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APOBEC3B was recently identified as a gain-of-function enzymatic source of mutagenesis,
which may offer novel therapeutic options with molecules that specifically target this
enzyme. In primary breast cancer, APOBEC3B mRNA is deregulated in a substantial pro-
portion of cases and its expression is associated with poor prognosis. However, its expres-
sion in breast cancer metastases, which are the main causes of breast cancer-related
death, remained to be elucidated.
Patients and methods
RNA was isolated from 55 primary breast cancers and paired metastases, including regional
lymph node (N = 20) and distant metastases (N = 35). APOBEC3B mRNA levels were mea-
sured by RT-qPCR. Expression levels of the primary tumors and corresponding metastases
were compared, including subgroup analysis by estrogen receptor (ER/ESR1) status.
Results
Overall, APOBEC3B mRNA levels of distant metastases were significantly higher as com-
pared to the corresponding primary breast tumor (P = 0.0015), an effect that was not seen
for loco-regional lymph node metastases (P = 0.23). Subgroup analysis by ER-status
showed that increased APOBEC3B levels in distant metastases were restricted to metasta-
ses arising from ER-positive primary breast cancers (P = 0.002). However, regarding ER-
negative primary tumors, only loco-regional lymph node metastases showed increased
APOBEC3B expression when compared to the corresponding primary tumor (P = 0.028).
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Conclusion
APOBEC3B mRNA levels are significantly higher in breast cancer metastases as compared
to the corresponding ER-positive primary tumors. This suggests a potential role for APO-
BEC3B in luminal breast cancer progression, and consequently, a promising role for anti-
APOBEC3B therapies in advanced stages of this frequent form of breast cancer.
Highlights
• APOBEC3B is a gain-of-function enzymatic source of mutagenesis.
• Levels are higher in breast metastases as compared to corresponding primary tumors.
• This implies a novel role for APOBEC3B during breast cancer progression.
• This makes APOBEC3B a promising target for anti-APOBEC3B therapies.
• Especially in advanced stages of breast cancer.
Introduction
Breast cancer is the fifth cause of overall cancer related death [1] and this mortality is largely
caused by progression of metastatic disease [2]. Therefore, one of the most important chal-
lenges in breast cancer research includes the genetic changes and molecular mechanisms by
which cancer cells acquire their metastatic ability. The generally accepted hypothesis is that
metastases are caused by multiple intricate steps that arise in the primary tumor site [3]. Nev-
ertheless, discordances between primary tumors and corresponding metastases are often
encountered [4]. However, therapies applied for disseminated disease are mainly based on pri-
mary tumor characteristics only. The study of molecular differences between matched primary
tumors and metastatic lesions may improve our understanding of disease progression and has
the potential to reveal novel, potentially targetable drivers of metastatic progression.
Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B (APOBEC3B) is a
member of the AID/APOBEC family of deaminases, which is recognized for its ability to
deaminate genomic DNA cytosines. APOBEC enzymes normally function in the innate
immune system and in the protection against viral pathogens, but these enzymes can also gen-
erate C!T mutations in the host genome [5]. Recently, several studies showed that APO-
BEC3B is a common enzymatic mutagenic factor affecting the evolution of different cancer
types, including breast cancer [5–19].
In breast cancer, APOBEC3BmRNA is substantially upregulated in one third of cases
and its expression is associated with mutational load, including certain driver mutations in
PIK3CA and TP53 [18,20]. Besides, multiple studies have postulated that APOBEC3B influ-
ences the development of metastases and drug resistance, especially in estrogen receptor alpha
(ERα)-positive breast cancer [5,21,22]. In line with this, we previously reported an association
between high APOBEC3BmRNA expression and poor outcome in a large cohort of patients
with ERα-positive breast cancer [23].
Since APOBEC3B is a gain-of-function mutagenic enzyme, it may be treatable with small
molecules [5,24], which could have an important role in the management of metastatic disease.
However, the expression of APOBEC3B in breast cancer metastases remained to be elucidated.
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ERBB2, human epidermal growth factor receptor 2;
NWO, Netherlands Organization of Scientific
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transcriptase polymerase chain reaction.
In this study, we therefore quantified APOBEC3BmRNA in primary breast cancers and




In this study we adhered to the Code of Conduct of the Federation of Medical Scientific Socie-
ties in the Netherlands (http://www.fmwv.nl) and the study making secondary use of human
materials has been approved by our ‘Medische Ethnische Toetsing Commissie’ (METC; MEC
02.953). The use of anonymous or coded left over material for scientific purposes is part of the
standard treatment agreement with patients and therefore informed consent was not required
according to Dutch law [25]. We selected 73 formalin-fixed paraffin-embedded (FFPE) pri-
mary breast cancers and corresponding metastases from the pathology archives of the Univer-
sity Medical Center Utrecht and Erasmus Medical Center Rotterdam. Each specimen was
reviewed by a pathologist to determine the percentage of invasive tumor cells. Inclusion crite-
ria were: availability of clinical and pathological data, the presence of enough tumor tissue
with the possibility to macro-dissect an area containing at least 50% tumor cells and good
RNA quality and quantity to reliably determine expression levels by RT-qPCR (see also
below). After applying these inclusion criteria, 55 paired primary tumors and metastases from
different sites remained, including those from regional lymph nodes (N = 20), brain (N = 14),
liver (N = 6), ovary (N = 4), lung (N = 4), bone (N = 4) and gastrointestinal tract (N = 3). Clini-
copathological characteristics included age, primary tumor size, histological subtype, Bloom
& Richardson score, ERα and human epidermal growth factor receptor 2 (HER2) expression
and regional lymph node status. Furthermore, overall survival (death due to any cause) was
reported. Detailed clinical information of this cohort is summarized in Table 1.
RNA isolation and quantitative reverse transcriptase polymerase chain
reaction (RT-qPCR)
Ten 10 μm slides were cut from the primary tumors and paired metastases. The first and last
sections (5 μm) were stained with hematoxylin and eosin to guide macro-dissection of the
tumor cells for RNA extraction. Total RNA was isolated from the macro-dissected sections
with the AllPrep DNA/RNA FFPE Kit (Qiagen) and resulting nucleic acid concentrations
were measured with a Nanodrop 2000 system (ThermoFisher Scientific). cDNA was generated
for 30 min at 48˚C with RevertAid H minus (ThermoFisher Scientific) and gene-specific pre-
amplified with Taqman PreAmp Master mix (ThermoFisher Scientific) for 15 cycles, followed
by Taqman probe—based real time PCR according to the manufacturer’s instructions in a
MX3000P Real-Time PCR System (Agilent). The following gene expression assays were
evaluated (all from ThermoFisher Scientific): APOBEC3B, Hs00358981_m1; EPCAM,
Hs00158980_m1; ESR1, Hs00174860_m1; ERBB2, Hs01001580_m1, KRT19, Hs01051611_gH;
PTPRC, Hs00236304_m1. mRNA levels were quantified relative to the average expression of
GUSB, Hs9999908_m1 and HMBS, Hs00609297_m1 using the delta Cq (dCq = 2^(average Cq
reference genes—Cq target gene)) method.
Quality and quantity control measurements for reliable quantitative
reverse transcriptase polymerase chain reaction (RT-qPCR)
For reliable RT-qPCR measurements, only samples that resulted in amplifiable products
within 25 cycles for the used reference gene set at an input of 50 ng total RNA (92.9% of the
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Clinical characteristics No of patients* Percentage of patients Median IQR Median IQR Median IQR6¼
All patients in this cohort 55 100% -6.14 -5.28 -3.11 -1.25 -2.98 -2.31
Age at surgery (years)
 40 10 18% -6.69 -4.62 -2.74 -1.40 -2.31 -2.89
41–55 21 38% -5.80 -5.95 -3.23 -1.46 -3.14 -1.41
56–70 20 36% -6.64 -4.16 -3.03 -1.25 -3.48 -7.68
> 70 5 9% -6.04 -2.08 -2.93 -0.54 -2.40 -1.09
P 6¼ 0.76 0.52 1.00
Tumor size
 2 cm 17 31% -6.14 -6.31 -3.03 -0.94 -2.72 -2.28
2 5 cm 27 49% -5.92 -2.25 -2.93 -1.40 -3.62 -7.65
> 5 cm 7 13% -6.91 -4.07 -3.17 -1.19 -3.27 -1.69
P6¼ 0.70 0.95 0.88
Histopathological subtypes†
Ductal 43 78% -5.80 -4.65 -2.93 -1.41 -3.27 -1.76
Lobular 8 15% -8.50 -3.92 -3.14 -0.85 -2.31 -4.90
Other 4 7% -6.43 -3.19 -3.37 -0.58 -1.23 -2.24
P$ 0.07 0.41 0.31
Bloom & Richardson grade
I + II 10 18% -6.39 -4.78 -3.11 -1.51 -6.94 -7.56
III 38 69% -5.78 -4.65 -3.15 -1.33 -2.92 -2.37
P$ 0.43 0.52 0.08
ESR1 status
Negative 22 40% -5.64 -3.79 -2.91 -1.24 -3.06 -2.00
Positive 33 60% -6.40 -4.69 -3.17 -1.35 -2.98 -2.81
P$ 0.15 0.39 0.88
ERBB2 status
Negative 43 78% -5.80 -5.01 -3.19 -1.06 -2.97 -2.90
Positive/amplified 12 22% -7.35 -3.70 -2.77 -1.59 -3.31 -1.67
P$ 0.04 0.11 0.96
Regional lymph node status
Negative 16 29% -5.64 -4.40 -3.17 -1.14 -2.84 -2.63
Positive 33 60% -6.40 -4.62 -3.00 -1.17 -2.98 -1.84
P$ 0.23 0.74 0.90
Time between primary tumor and studied metastasis
 24 months 33 60% -5.92 -5.45 -2.88 -1.16 -2.85 -2.09
> 24 months 22 40% -6.43 -4.09 -3.24 -0.93 -3.20 -2.28
P6¼ 0.97 0.42 0.33
Overall survival status
Alive 22 40% -5.92 -2.52 -3.11 -1.48 -3.67 -8.34
Deceased 33 60% -6.65 -5.03 -3.11 -0.95 -2.81 -1.68
P$ 0.21 0.62 0.20
AVG epithelial; average mRNA level of KRT19 and EPCAM. IQR; interquartile range.
* Due to missing values numbers do not always add up to 55.
6¼ Spearman correlation significance (2-tailed).
$ Mann-Whitney Test significance (2-tailed).
† mRNA expression of ductal and lobular breast cancer was compared.
doi:10.1371/journal.pone.0171343.t001
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samples) were considered to be of good quality to reliably determine RT-qPCR levels. Further-
more, a serially diluted FFPE breast tumor sample was included in each experiment to evaluate
the linear amplification and efficiencies for all genes included in the panel and absence of
amplification in the absence of reverse transcriptase. All gene transcripts were 100% efficient
amplified (range 94%-102%) and were negative in the absence of reverse transcriptase.
Estrogen receptor (ER/ESR1) and HER2 (HER2/ERBB2) status
Because data regarding ER and HER2 expression on protein level of our data set was incom-
plete, ESR1 and ERBB2mRNA expression was used to determine ESR1 and ERBB2mRNA sta-
tus (using a cut-off dCq for ESR1>1 and ERBB2>3.5 by optimal binning for n = 92 and n = 87
overlapping samples, respectively (Fig 1)). Because ER and HER2 are determined on protein
level in daily clinical practice (using a scoring system according to national guidelines [26,27]),
we investigated whether the ESR1 and ERBB2mRNA status accurately reflected the ER and
HER2 protein status as reported in the pathology reports in samples with known receptor pro-
tein status (Fig 1). These cut-offs resulted in a sensitivity of 0.88 and specificity of 0.85 for
ESR1 and in a sensitivity of 0.89 and specificity of 0.97 for ERBB2.
Statistics
SPSS version 23 was used for all statistical analyses. The Kolmogorov-Smirnov and Shapiro-
Wilk tests were used to test for normality of the distributions. To compare mean values
between two or more groups, the Mann-Whitney U Test or Kruskal-Wallis test was used, fol-
lowed by a test for trend if appropriate. To compare values measured in primary cancers and
paired metastases, the paired Wilcoxon Signed Ranks test was used. To correlate linear vari-
ables, the Spearman Rank Correlation test was used. P-values 0.05 were considered statisti-
cally significant.
Results
APOBEC3B mRNA expression in primary breast cancer
Since the Kolmogorov-Smirnov and Shapiro-Wilk tests showed that our data were not always
normally distributed, we tested all our data non-parametrically. First, we correlated the levels
of APOBEC3BmRNA measured in the primary tumors with traditional clinicopathological
characteristics (Table 1). Besides a higher expression of APOBEC3BmRNA in ERBB2 negative
Fig 1. Correlation of ER and HER2 protein status with ESR1 and ERBB2 mRNA levels. Arrows indicate
used cut-off value.
doi:10.1371/journal.pone.0171343.g001
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tumors when compared to ERBB2 positive tumors (Spearman’s Rho = -0.46, P = 0.002), APO-
BEC3BmRNA levels were not correlated to any of the studied parameters.
To ensure that different levels of tumor cells or inflammatory cells in the primary tumors
and their matched metastasis did not bias our data, we quantified the mRNA levels of KRT19
and EPCAM (as a measure for epithelial content) and PTPRC (the gene for the common leuko-
cyte antigen CD45, as a measure for the presence of lymphocytes). Although a weak positive
correlation was observed between APOBEC3BmRNA levels and epithelial content in the com-
plete cohort (Spearman’s Rho = 0.21, P = 0.031, N = 110), no significant correlations were
observed between the mRNA levels of APOBEC3B and epithelial or infiltrate content when
analyzed separately for the primary tumors and the metastases (Spearman correlation signifi-
cance P> 0.05). In addition, epithelial and infiltrate content did not differ significantly
between the primary tumors and matched metastases (paired Wilcoxon Signed Rank test
P> 0.05).
APOBEC3B mRNA expression in primary breast cancer and paired
metastases
Next, we correlated APOBEC3BmRNA expression in primary tumors and their matched
metastases. This analysis revealed that APOBEC3BmRNA levels were significantly higher in
the matched distant metastases as compared to the primary tumors (paired Wilcoxon Signed
Rank test P = 0.0015, Fig 2A and Table 2). In contrast, no difference was perceived between
primary tumors and matched loco-regional lymph node metastases (paired Wilcoxon Signed
Rank test P = 0.23)), while levels remained significantly elevated for the cohort with distant
metastases (paired Wilcoxon Signed Rank test P = 0.02); (Table 2). Also, APOBEC3BmRNA
levels measured in distant metastases (N = 35) showed a trend towards higher expression
when compared to regional lymph node metastases (N = 20) of unmatched cases (Mann-Whit-
ney U test P = 0.08, Fig 2A). No such trend was observed in primary tumors that disseminated
either to loco-regional or distant locations (Mann-Whitney U test P = 0.42, Fig 2A).
Subgroup analysis by distant metastatic site showed increased APOBEC3B expression for all
locations, particularly for liver and ovary, although no significance was reached for any of the
relatively small subgroups (paired Wilcoxon Signed Ranks test P> 0.05, Fig 2B and Table 2).
We also compared mRNA levels measured in primary tumors according to distant metastatic
site. These analyses showed that APOBEC3BmRNA levels were lowest in primary tumors that
metastasized to the ovaries and gastro-intestinal sites and highest in primary tumors that
metastasized to lung, brain or bone (Kruskal-Wallis test P = 0.030), Fig 2B).
APOBEC3B mRNA expression according to ESR1 and ERBB2 status of
the primary tumor
We observed no association between APOBEC3BmRNA levels and ESR1-status (Table 1). Sev-
eral previous studies, however, showed higher APOBEC3BmRNA expression in ERα-negative
tumors compared to ERα-positive tumors [23,28,29]. Notably, in these studies, high APO-
BEC3B expression levels were only associated with poor prognosis for ERα-positive primary
breast tumors. We therefore categorized our primary cohort into ESR1-positive and ESR1-neg-
ative primary tumors (Fig 2C and 2D). For the ESR1-positive primary tumors, a significantly
higher expression was seen in paired distant metastases, but not in loco-regional metastases
(Fig 2C; paired Wilcoxon Signed Ranks Test P = 0.002 and 0.53, respectively). In contrast, for
the ESR1-negative primary tumors a significantly higher expression was seen in loco-regional
metastases, but not in distant metastases (Fig 2D; paired Wilcoxon Signed Ranks Test
Progressive APOBEC3B mRNA expression in distant breast cancer metastases
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P = 0.028 and 0.81, respectively). Receptor conversion from an ESR1-positive primary tumor
to an ESR1-negative metastasis could not explain this finding (Table 3).
No such difference was seen after categorizing our patients according to ERBB2-status. Irre-
spective of ERBB2-status,APOBEC3B levels were only higher in the distant metastases and not
in the loco-regional lymph nodes when compared to the paired primary tumor (paired Wil-
coxon Signed Ranks Test P< 0.05 and> 0.05, respectively).
Discussion
APOBEC3B is thought to affect the evolution of breast cancer by somatically mutagenizing the
cancer genome, which could potentially be abrogated by therapeutic intervention [5]. Previous
studies investigated APOBEC3BmRNA expression in primary breast tumors and paired nor-
mal tissue. These studies reported upregulation in primary tumors compared to normal tissue,
especially in ERα-negative cases [17,28]. However, metastatic disease remains the major cause
of breast cancer related mortality and several studies reported discordances of (epi) genetic
and immunohistochemical markers between primary tumors and matched metastases [4,30–
34]. To the best of our knowledge, no data is available regarding APOBEC3B expression in
Fig 2. APOBEC3B mRNA expression differences between primary breast tumors and paired metastases. (A) APOBEC3B mRNA expression in
primary breast tumors versus paired loco-regional and distant metastases. (B) APOBEC3B mRNA expression in primary breast tumors versus paired
metastases, subdivided per location of metastasis (ovary (N = 4); liver (N = 6); bone (N = 4); brain (N = 14); lung (N = 5) and gastro-intestinal tract
(N = 3). (C) APOBEC3B mRNA expression in ESR1-positive primary breast tumors versus paired distant and loco-regional metastases. (D)
APOBEC3B mRNA expression in ESR1-negative primary breast tumors versus paired distant and loco-regional metastases. P-values obtained by
paired Wilcoxon Signed Ranks test (2-tailed).
doi:10.1371/journal.pone.0171343.g002
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Clinical parameter No of patients* Percentage of patients Mean SD Mean SD Mean SD
Tissue origin
Primary tumor 55 100% -6.51 2.53 -3.04 1.07 -3.98 3.23
Paired Metastasis 55 100% -5.36 2.39 -2.85 1.08 -4.48 2.84
Pǂ 0.0015 0.20 0.26
According metastatic site
Loco-regional lymph node
Primary tumor 20 36% -6.87 2.55 -2.82 0.91 -3.88 2.89
Paired Metastasis 20 36% -6.12 2.68 -2.63 0.89 -3.42 3.03
Pǂ 0.23 0.31 0.49
Distant metastases
Primary tumor 35 64% -6.30 2.54 -3.16 1.15 -4.30 3.34
Paired Metastasis 35 64% -4.93 2.13 -2.98 1.16 -4.82 2.80
Pǂ 0.002 0.38 0.39
Distant metastasis specified
Ovary
Primary tumor 4 7% -9.25 1.39 -3.31 1.25 -5.53 5.25
Paired Metastasis 4 7% -5.51 0.74 -3.03 1.20 -3.99 0.93
Pǂ 0.07 0.72 0.47
GI tract
Primary tumor 3 5% -7.79 3.84 -3.32 0.20 -1.83 1.10
Paired Metastasis 3 5% -6.96 0.54 -3.93 1.88 -4.41 4.88
Pǂ 0.59 0.59 0.11
Liver
Primary tumor 6 11% -7.59 2.65 -3.16 1.57 -2.66 1.35
Paired Metastasis 6 11% -5.10 2.45 -2.20 1.17 -4.76 2.71
Pǂ 0.08 0.17 0.028
Bone
Primary tumor 4 7% -5.82 1.23 -3.01 1.28 -5.04 3.31
Paired Metastasis 4 7% -4.98 3.85 -2.63 0.96 -4.11 3.97
Pǂ 0.47 0.27 0.47
Brain
Primary tumor 14 25% -5.29 2.06 -3.10 1.03 -5.53 3.58
Paired Metastasis 14 25% -4.46 2.00 -2.95 0.81 -5.67 2.82
Pǂ 0.20 0.68 0.98
Lung
Primary tumor 4 7% -4.32 1.45 -3.29 1.69 -2.35 1.59
Paired Metastasis 4 7% -4.21 1.49 -3.82 1.47 -3.76 1.66
Pǂ 0.72 0.47 0.14
SD; standard deviation. AVG epithelial; average mRNA level of KRT19 and EPCAM.
* Due to missing values, numbers don’t always add up to 55.
ǂ Paired Wilcoxon Signed Ranks Test significance (2-tailed).
doi:10.1371/journal.pone.0171343.t002
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breast cancer metastases. Therefore, we set out to evaluate APOBEC3BmRNA expression in
primary breast cancer and matched metastases. Importantly, we encountered a significant
increase in APOBEC3BmRNA levels in the metastases compared to their corresponding pri-
mary tumor. Furthermore, distant metastases showed higher expression than loco-regional
lymph node metastases. This implies a role for APOBEC3B not only at the stage of the primary
tumor but also, and according to our data even more dominantly, during tumor evolution of
metastatic breast cancer.
Previous studies reported an association between APOBEC3B expression and aggressive
characteristics of the primary breast cancer, including high histologic grade, genomic grade,
advanced stage, negative ERα status and HER2/ERBB2 amplification [21,23,28,29,35]. In this
current, more concise study with a special focus on breast cancer metastases, we only observed
a negative association between APOBEC3B and ERBB2mRNA levels in both the primary
tumor (Table 1) and the metastases (data not shown). However, our sample size was relatively
small with a relatively high number of cases with loco-regional (36%) and brain metastases
(25%), which could have biased our results.
Overall, we did not find a correlation between APOBEC3B and ESR1-status of the primary
tumor, while previous studies reported higher APOBEC3BmRNA expression in ERα-negative
tumors compared to ERα-positive tumors ([23,28,29]. Interestingly, for our ESR1-negative pri-
mary cases, a significantly higher expression of APOBEC3Bwas seen in paired loco-regional
metastases only and not in paired distant metastases. For our ESR1-positive primary cases on
the other hand, a significantly higher expression was seen in paired distant metastases and not
in the loco-regional lymph nodes. This is especially noteworthy in view of our previous find-
ing, that high levels of APOBEC3Bwere only associated with poor prognosis in ESR1-positive
primary breast cancers, and not in ESR1-negative cases [23].
Irrespective of ESR1-status, we showed that APOBEC3B expression was increased in distant
metastases compared to the corresponding primary tumor, with highest expression in liver,
lung, brain and bone metastases. APOBEC3B thus seems not only needed for breast cancer
progression, but also for maintenance of the metastasis in distant environments. Since APO-
BEC3B is upregulated in numerous cancer types we wondered if these findings could be
explained by the micro-environment of the distant site. In an article of Burns et al. [7], APO-
BEC3B expression levels determined by RNA-seq showed a lower expression in normal brain
and ovarian tissue relative to normal breast tissue. Furthermore, brain tumors (low-grade gli-
oma, glioblastoma multiforme) and ovarian tumors (serous cystadenocarcinoma) also had
lower APOBEC3B expression levels than breast carcinoma. This might imply that the higher
APOBEC3BmRNA levels we found in breast cancer brain and ovarian metastases are indepen-
dent of the micro-environment at these locations. Furthermore, since the pattern of APO-
BEC3B expression in primary tumors is retained and even increased in paired metastases, and
shows a trend toward a possible metastatic location-specific pattern, one could envision that
Table 3. ESR1 conversions from primary tumor to metastasis specified by site of metastasis.
ESR1 conversion primary to metastasis Metastasis type N dCq APOBEC3B dCq APOBEC3B P-value* P-value*
Primary (Average) Metastasis (Average)
Not converted loco-regional lymph node 15 -6.4 -5.97 0.61 0.032
distant metastasis 27 -5.86 -4.87 0.015
ESR1- primary to ESR1+metastasis loco-regional lymph node 5 -8.26 -6.57 0.11 0.041
ESR1+ primary to ESR1- metastasis distant metastasis 8 -7.8 -5.16 0.07
* Wilcoxon Signed Ranks Test
doi:10.1371/journal.pone.0171343.t003
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the primary tumor is already ‘primed’ for an eventual site of dissemination. This should how-
ever be validated in a larger cohort and also at the protein level. To this end, we tried 2 com-
mercially available APOBEC3B antibodies (PAB2474 from Abnova and Anti-APOBEC3B
antibody—N-terminal ab191695 from Abcam). However, despite various efforts, we had to
conclude that detecting APOBEC3B in breast cancer by immunohistochemistry with these
currently commercially available antibodies should be considered unreliable due to non-spe-
cific staining. Hopefully, now that APOBEC3B is gaining increased interest, more specific anti-
bodies will become available soon to confirm our findings at the protein level.
In theory, tumor heterogeneity could explain some of the observed differences between
primary tumors and paired metastases. However, the reported distinct APOBEC3BmRNA
expression levels of the primary tumor that were largely retained or increased in the paired
metastases could not solely be explained by heterogeneity. In daily practice, the majority of
metastases are not resected or biopsied. This likely resulted in a selection bias, since we only
included primary tumors with available material of the paired metastasis. Another weakness of
our study is the relatively small number of patients with distant metastases, which limited the
reliability of subgroup analysis according to metastatic site.
In conclusion, our findings add to the knowledge that APOBEC3B contributes to breast
cancer progression and has now extended this to metastatic disease. Since APOBEC3B expres-
sion is at least retained and often even increased in distant metastases, our data suggest that it
might also be an effective interventional candidate for disseminated breast cancer.
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